Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03655756 · ClinicalTrials.gov registry record · Early Phase 1
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
A Early Phase 1 study, sponsored by TuHURA Biosciences.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT03655756 is a Early Phase 1 study that has completed, run by TuHURA Biosciences. The registered enrollment target is 7 participants.
The verdict
NCT03655756, a Early Phase 1 study, has completed, sponsored by TuHURA Biosciences.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected). These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-7 business days for any delayed adverse events.
Interventions
- BIOLOGICAL IFx-Hu2.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2020-11-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03655756
The ClinicalTrials.gov registry entry for NCT03655756 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TuHURA Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IFx-Hu2.0 is the first listed.
NCT03655756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03655756 about?
NCT03655756 is a clinical study titled "pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma". Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected). These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-7 business...
What is the current status of trial NCT03655756?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2018-11-05. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT03655756?
The interventions under investigation include: IFx-Hu2.0 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03655756?
This trial is sponsored by TuHURA Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.